Candela Corp., a subsidiary of Syneron Medical Ltd., announced that it has received registration approval from the Japanese Ministry of Health, Labour and Welfare to market its Vbeam long-pulsed dye laser system for the treatment of vascular conditions. It is the first long-pulsed dye laser system approved for use in Japan.

“This marks a significant milestone in our global distribution, as physicians and patients in Japan will now have full access to the gold standard treatments that Vbeam offers,” said Lou Scafuri, chief executive officer of Syneron.

The approval will also help facilitate health insurance payments to physicians and patients, allowing for certain medical conditions to be reimbursed. “This helps physicians and patients alike, offering a new and improved treatment option for high-demand vascular lesion procedures, such as port wine stain and hemangiomas,” said Dr. Taro Kono, chief of laser section, department of plastic and reconstructive surgery, Tokyo Women’s Medical University.

“Our patients who suffer from cutaneous vascular lesions will be pleased to have access to Vbeam,” said Muneo Miyasaka, professor in the department of plastic and reconstructive surgery, Tokai University. “The Japanese Society of Plastic and Reconstructive Surgery recognizes the critical need for this system and fully supports the approval of the Vbeam long-pulsed dye laser.”

For more information, visit:  www.candelalaser.com